文献速递主动脉疾病

二氧化碳引导EVAR的跨中心辐射剂量差异:零碘对比剂多中心前瞻研究

Inter-Center Radiation Variability in CO2-Guided EVAR: Lessons From the Zero Iodine Contrast Multicenter Prospective Study.
PubMed 文献 · J Endovasc Ther · 2026-04-21

该多中心前瞻性观察研究纳入10中心293例以CO2为唯一对比剂行EVAR的患者,记录剂量面积乘积(DAP)与参考空气比释动能(Kar)。中位DAP为189 Gy·cm2,Kar为626.5 mGy,中心间差异显著(p<0.001);新型血管造影系统DAP中位90 Gy·cm2,显著低于旧系统的191 Gy·cm2(p<0.001)。经低剂量方案、现代设备及CO2-DSA同步等优化,总剂量降低56%(p<0.001),最终中位DAP为28.5 Gy·cm2。

要点

  • CO2引导EVAR的辐射剂量存在显著中心间差异,受造影系统代次与软件同步方案影响。
  • 新型造影系统联合低剂量方案及CO2-DSA同步可大幅降低DAP,最终中位28.5 Gy·cm2。
  • 优化后辐射剂量可与传统碘对比剂EVAR的DRL(100–200 Gy·cm2)相媲美。

核心结论

  • CO2引导EVAR辐射剂量变异大,现代系统联合优化方案可使DAP降至与传统碘对比剂EVAR相当的水平。

研究设计与样本

  • 前瞻性、多中心、全国性、非随机、研究者发起的观察性研究,纳入10中心293例以CO2为唯一对比剂的EVAR患者,记录剂量学参数。

主要发现

  • 总体中位DAP为189 Gy·cm2(IQR 107–285),中位Kar为626.5 mGy(IQR 145.5–1373.5),中心间差异显著(p<0.001)。
  • 新型血管造影系统中位DAP为90 Gy·cm2(IQR 71–153),显著低于旧系统的191 Gy·cm2(IQR 111–409;p<0.001)。
  • 序贯优化实现剂量递减:低剂量方案降低38.5%,现代设备降低52.3%,CO2-DSA同步后总降低56%(p<0.001),最终中位DAP为28.5 Gy·cm2。

关键数值与推荐

  • 当前基于碘对比剂的EVAR诊断参考水平(DRL)为100–200 Gy·cm2。
  • CO2引导EVAR总体中位DAP 189 Gy·cm2,Kar 626.5 mGy。
  • 新型系统DAP中位90 Gy·cm2,旧系统191 Gy·cm2(p<0.001)。
  • 优化后最终中位DAP 28.5 Gy·cm2,总剂量降低56%(p<0.001)。

临床怎么用

  • 优先选用新型血管造影系统并启用低剂量协议,可显著降低CO2引导EVAR的辐射剂量。
  • 采用CO2-DSA同步技术可进一步将DAP降至与传统碘对比剂EVAR相当的水平。
  • 各中心应关注设备代次与软件同步方案对辐射剂量的影响,制定本地优化策略。

局限性

  • 本研究为非随机观察性研究,未设对照组。
  • 优化策略的评估仅在单一研究站点进行。
  • 中心间差异显著,结果可能受各中心操作习惯与设备配置影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Current diagnostic reference levels (DRLs) for endovascular aortic repair (EVAR), based on iodinated contrast media (ICM) protocols, range from 100 to 200 Gy·cm2. As CO2 is a negative contrast agent requiring digital subtraction angiography (DSA) for visualization, it may be associated with increased radiation exposure. This multicenter study presents the largest prospective data set to date evaluating radiation dose during EVAR using CO2 angiography alone with an automated injector. METHODS: A prospective, multicenter, nationwide, nonrandomized, investigator-initiated observational study of dosimetry recorded during EVAR procedures with CO2 as exclusive contrast medium was conducted. Primary endpoints included dose-area product (DAP) and reference air kerma (Kar) measurements across all participating centers. Secondary objectives focused on evaluating optimization strategies to reduce radiation exposure for both patients and operators at a single investigational site. RESULTS: A total of 293 patients were enrolled across 10 centers, between January 2023 and January 2024, median DAP and Kar were 189 Gy·cm2 (interquartile range [IQR] 107-285) and 626.5 mGy (IQR 145.5-1373.5), respectively, with significant inter-center variability (all p<0.001). Newer angiographic systems demonstrated markedly lower DAP (median: 90 Gy·cm2, IQR 71-153) vs older systems (191 Gy·cm2, IQR 111-409; p<0.001). Through sequential optimization, we achieved progressive dose reductions: 38.5% via low-dose protocols, 52.3% with modern equipment, culminating in a 56% overall reduction (p<0.001) with synchronized CO2-DSA-yielding a final median DAP of 28.5 Gy·cm2. CONCLUSIONS: CO2-guided EVAR exhibits substantial radiation dose variability, driven by angiographic system generation, software, and synchronization protocols. Modern systems with optimized low-dose protocols and CO2-DSA synchronization reduce radiation exposure to levels comparable to ICM-based EVAR.Clinical ImpactThis large multicenter prospective study establishes a reliable radiation dose benchmarks for CO2-guided endovascular aortic repair (EVAR), showing that modern angiographic systems with optimized low-dose protocols and synchronized CO2-digital subtraction angiography achieve median dose-area product values comparable with conventional iodinated contrast media EVAR, thereby dispelling concerns about excessive radiation exposure with CO2-guided EVAR.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Chisci E, Ferrero E, Antonello M, et al. Inter-Center Radiation Variability in CO2-Guided EVAR: Lessons From the Zero Iodine Contrast Multicenter Prospective Study. J Endovasc Ther. 2026. PMID: 42011971. doi:10.1177/15266028261440717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。